InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT05463796
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer Risk
- Cancer Predisposition Syndrome
- Hereditary Cancer Prediction
- Childhood Cancer Survivors
- Adult Cancer Survivors
- IARC Carcinogens
- Smoking History
- Lung Cancer
- Ductal/Lobular Carcinoma
- Barrett Esophagus
- Pancreatic Precursor Lesions
- Colonic Dysplasia/Adenomata
- Non-Alcoholic Fatty Liver Disease
- Non Alcoholic Steatohepatitis
- Cirrhosis
- High Grade Prostatic Epithelial Neoplasia
- High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ
- Adenomatous Hyperplasia
- High-risk Oral Precancerous Diseases
- Melanocytic Lesion, Adult
- Hematologic Malignancy
- Lung; Node
- Serous Tubal Intraepithelial Carcinoma
- Endometrial Intraepithelial Neoplasia
- Cervical and Endocervical Carcinoma in Situ
- Vulvar Intraepithelial Neoplasia
- Nephrogenic Rests
- Benign Bone Lesions With Risk of Malignant Degeneration
- Giant Cell Tumor
- Osteochondroma
- Spitz Nevus
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- Any age
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.